PMID- 25612559
OWN - NLM
STAT- MEDLINE
DCOM- 20160527
LR  - 20210103
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 138
IP  - 2
DP  - 2016 Jan 15
TI  - Does the nature of residual immune function explain the differential risk of 
      non-melanoma skin cancer development in immunosuppressed organ transplant 
      recipients?
PG  - 281-92
LID - 10.1002/ijc.29450 [doi]
AB  - Patients receiving immunosuppression to prevent organ transplant rejection are at 
      a greatly increased risk of developing nonmelanoma skin cancer. In recent years a 
      correlation has been identified between the class of immunosuppressant that these 
      patients receive and their subsequent cancer risk; in particular, patients 
      switched from calcineurin inhibitors to mammalian target of rapamycin (mTOR) 
      inhibitors not only displayed a dramatic reduction in new tumor formation but 
      also in some cases a regression of their existing lesions. Studies of cancer 
      models in mice and cell lines in the laboratory have attributed these 
      discrepancies in cancer risk to the ability of immunosuppressants such as mTOR 
      inhibitors to elicit direct anticancer effects, including suppressing 
      angiogenesis and increasing autophagy-mediated DNA repair. Recent evidence from 
      the immunological literature however, suggests a significant alternative 
      contribution of mTOR inhibitors; namely the promotion of memory T-cell function. 
      Recent advances in understanding memory T-cell establishment and the 
      demonstration of their critical role in long-term immunity make it timely to 
      review the available evidence as to whether the improved nonmelanoma skin cancer 
      outcome shown by patients switched to mTOR inhibitor treatment regimens may be 
      associated with the retainment of memory T-cell function.
CI  - (c) 2015 UICC.
FAU - Jung, Ji-Won
AU  - Jung JW
AD  - The University of Queensland Diamantina Institute, The University of Queensland, 
      Translational Research Institute, Brisbane, QLD.
FAU - Overgaard, Nana H
AU  - Overgaard NH
AD  - The University of Queensland Diamantina Institute, The University of Queensland, 
      Translational Research Institute, Brisbane, QLD.
AD  - Center for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen 
      University Hospital, Herlev, Denmark.
FAU - Burke, Michael T
AU  - Burke MT
AD  - Department of Renal Medicine, The University of Queensland, Princess Alexandra 
      Hospital, Brisbane, QLD.
FAU - Isbel, Nicole
AU  - Isbel N
AD  - Department of Renal Medicine, The University of Queensland, Princess Alexandra 
      Hospital, Brisbane, QLD.
FAU - Frazer, Ian H
AU  - Frazer IH
AD  - The University of Queensland Diamantina Institute, The University of Queensland, 
      Translational Research Institute, Brisbane, QLD.
FAU - Simpson, Fiona
AU  - Simpson F
AD  - The University of Queensland Diamantina Institute, The University of Queensland, 
      Translational Research Institute, Brisbane, QLD.
FAU - Wells, James W
AU  - Wells JW
AUID- ORCID: 0000-0002-9618-6940
AD  - The University of Queensland Diamantina Institute, The University of Queensland, 
      Translational Research Institute, Brisbane, QLD.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150205
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Immunocompromised Host/*immunology
MH  - Immunosuppressive Agents/*adverse effects
MH  - Organ Transplantation/*adverse effects
MH  - Risk Factors
MH  - Skin Neoplasms/*immunology
MH  - T-Lymphocytes/*drug effects/immunology
MH  - Transplant Recipients
OTO - NOTNLM
OT  - T-cells
OT  - immunosuppression
OT  - nonmelanoma skin cancer
OT  - organ transplant recipient
EDAT- 2015/01/24 06:00
MHDA- 2016/05/28 06:00
CRDT- 2015/01/24 06:00
PHST- 2014/07/09 00:00 [received]
PHST- 2015/01/08 00:00 [accepted]
PHST- 2015/01/24 06:00 [entrez]
PHST- 2015/01/24 06:00 [pubmed]
PHST- 2016/05/28 06:00 [medline]
AID - 10.1002/ijc.29450 [doi]
PST - ppublish
SO  - Int J Cancer. 2016 Jan 15;138(2):281-92. doi: 10.1002/ijc.29450. Epub 2015 Feb 5.